SEARCH:   Advanced

Blood, 15 November 2006, Vol. 108, No. 10, pp. 3280-3288. Prepublished online as a Blood First Edition Paper on July 13, 2006; DOI 10.1182/blood-2006-04-014324. This Article Full Text (PDF) All Versions of this Article: blood-2006-04-014324v1 108/10/3280    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Frohling, S. Articles by Dohner, H. Search for Related Content PubMed PubMed Citation Articles by Frohling, S. Articles by Dohner, H. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 26, 2006 Accepted July 6, 2006 Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B Stefan Frohling, Richard F Schlenk, Sabine Kayser, Martina Morhardt, Axel Benner, Konstanze Dohner, and Hartmut Dohner* Dept. of Internal Medicine III, University Hospital of Ulm,Germany; Brigham and Women's Hospital,USA Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany Central Unit Biostatistics, German Cancer Research Center, Heidelberg, Germany * Corresponding author; email: hartmut.doehner{at}uniklinik-ulm.de. To assess the prognostic impact of cytogenetics in elderly acute myeloid leukemia (AML) patients receiving intensive induction and consolidation treatment according to a single protocol specifically designed for patients above age 60, pretreatment samples from 361 patients registered for the AML HD98-B trial of the German-Austrian AML Study Group were analyzed by chromosome banding and fluorescence in situ hybridization, and cytogenetic findings were correlated with outcome. Using a proportional hazards model with backward selection, 3 prognostic subgroups were identified based on the influence of cytogenetic abnormalities on overall survival (OS): low-risk, t(15;17) and inv(16) (25 of 361 patients, 7%); standard-risk, normal karyotype, t(8;21), t(11q23), +8 within a noncomplex karyotype, and +11 within a noncomplex karyotype (208 of 361 patients, 58%); high-risk, all other aberrations (128 of 361 patients, 35%). On multivariate analysis, high-risk cytogenetics (hazard ratio, 2.24) and age above 70 (hazard ratio, 2.34) were independent prognostic factors affecting OS, and stratification according to these parameters demonstrated that a large subgroup of patients (55%), characterized by age 70 or older or high-risk cytogenetics, or both, had very unfavorable treatment results despite intensive chemotherapy. Thus, karyotype and age are major determinants of outcome in elderly AML patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Older AML patients: fit for what? Richard M. Stone Blood 2006 108: 3232-3233. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020